Dr. Ashok Srivastava is Chief Executive Officer, Chief Medical Officer and founder of ClinFomatrix Oncology. He was also founder and Chief Medical Officer of Global Pharmatek clinical and drug safety Oncology and Chief Medical Officer of CareBeyond – A Radiation Cancer Center in USA. Dr. Srivastava is a Leader in drug safety, pharmacovigilance of hematology, oncology drugs and has extensive global drug safety and pharmacovigilance experience in USA and India. He has more than 15 years of experience in drug development , medical affairs and commercialization of cancer drugs including immuno oncology, radiopharmaceutical and supportive care; Phase I – 4, marketing commercialization of Hematology, Oncology and immuno-onaology drugs in USA , EU and Japan. He is leader in Cancer Drug Development Worldwide large Phase 2 and 3 Clinical Trials in many countries. He contributed to 21-INDs and 7-NDAs of Cancer Drugs and supportive care, acquisition, merger of company for more than $300 million . He received his clinical, medical training & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center, Daiichi, Sumitomo, Pharmacia, Pfizer, Sopherion Oncology., Eisai Oncology, Anges and Spectrum Pharmaceuticals. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India ; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Nagasaki, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive metastatic breast cancer patients and latuda (Lurasidone) for schizophrenia He is one of the inventors of Japanese encephalitis vaccine (IXIARO) . He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous National & International prestigious medical awards and recognitions from United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor to Poniard Pharmaceutical for small cell lung cancer in USA, EU and India. Dr. Srivastava is member of numerous prestigious organizations; America’s Top Oncologist of the years 2007, 2008, 2011, Breast Cancer Foundation , Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer. Dr. Srivastava is a strategic medical advisor and Board Member to several pharma in USA for clinical, regulatory and supervises cancer drug development . Recently Dr. Srivastava was awarded membership of Japan External Trade Organization, USA. Dr. Srivastava brought 2 cancer drugs & a vaccine in global market for approx 3 – 3.5 billion $ global sales. He serves as board of directors for oncology virtual pharma companies in USA.